Leading the Way in Life Science Technologies

GEN Exclusives

More »

May. 1, Vol. 32, No. 9

    • Point of View

      • Step Up for Biotechnology
      • Ron Cohen, M.D.
      • The U.S. is now facing unprecedented competition from around the globe to be the leader in biomedical research. In 2008, China pledged to invest $12 billion in drug development, and in 2011, the Chinese government named biotechnology as one of seven ... more »
      • Drivers and Hurdles for qPCR
      • Mikael Kubista, Ph.D.
      • According to a recent report on the gene-amplification technologies market from Global Industry Analysts, there are close to 70,000 bioresearchers using real-time quantitative PCR (qPCR) in North America alone. They spend $740 million annually on in ... more »
      • Leading-Edge Separation Techniques
      • Angelo DePalma, Ph.D.
      • Five presentations on protein purification at last month’s “Bioprocess International Europe Conference” in Prague provided clear and detailed insights on the latest thinking on how to best handle therapeutic biomolecules. Günther Jagschies, P ... more »
      • Mathematics Transforming Bioresearch
      • Mitzi Perdue
      • Human and animal health, agriculture, energy production, environmental protection, and a host of other activities of interest to humans have something startling in common: the key to improvements in all of them is likely to require a significant com ... more »
      • Telling the Story of Biotechnology
      • Donna Lock
      • Biotechnologists are in the tomorrow business. They strive to innovate, invent, and make progress. They must; survival depends on it. Biotechnologists are future-oriented. Yet, biotechnologists are also steeped in history. They swim in the past an ... more »
    • Wall Street BioBeat

    • Tutorials

      • Bottom Reading of Cell-Based Assays
      • E. J. Dell
      • When the Nobel Prize for Chemistry was awarded to Osamu Shimomura, Martin Chalfie, and Roger Y. Tsien for the discovery and development of the green fluorescent protein (GFP) in 2008, researchers around the world were already using GFP (and the many ... more »
    • Corporate Profile

      • Targeting Unmet Needs in Oncology
      • Carol Potera
      • MolMed (short for Molecular Medicine) has two anticancer therapies in Phase III clinical trials. The candidates are based on distinctly different technology platforms. MolMed, headquartered in Milan, Italy, at the San Raffaele Biomedical Science P ... more »
    • BioMarket Trends

      • Next-Gen Sequencing Services
      • Christianne Bird
      • Much of the media and investor attention paid to next-generation sequencing surrounds the instrumentation market. However, the sequencing services market is growing as well, at a projected compound annual growth rate (CAGR) of 28% from 2011 to 2016, ... more »
    • Gene Therapy Briefs

      • Gene Therapy Briefs
      • Amsterdam Molecular Therapeutics published data in the Journal of Clinical Endocrinology & Metabolism demonstrating that one-time administration of the gene therapy Glybera® (alipogene tiparvovec) in five patients markedly improved chylom ... more »
    • People in the News

      • People in the News
      • Mike Evans, Ph.D. , is now nonexecutive chairman for TAP Biosystems. Dr. Evans had been a nonexecutive director of TAP since 2005 and has worked in the life science industry for over 20 years with companies including GE Healthcare and Oxford Gene Te ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »